{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"21"}],"title":"Progression of Disease"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"Complete Response (CR): Cytologic and radiographic CR will be evaluated separately, since patients with cytologic clearing and clinical response may continue to have residual abnormalities on MRI scans. Patients with a CR must also have stable or improved neurologic exam.\n\nStable Disease (SD): Exists when a patient fails to fulfill the criteria for either complete or partial response or progressive disease.\n\nProgressive Disease (PD): An increase of at least 50% in the absolute number of malignant cells in the CSF OR, in -solid tumor patients, an increase of greater than 25% in the size of measurable lesions on MR scan OR the recurrence of malignant cells in the CSF or new lesions on MR after a patient has attained a complete remission OR evidence of clinical neurologic progression. New sites of or increasing evidence of leptomeningeal enhancement that is not \"measurable\" will also be considered evidence of disease progression.","groups":[{"description":"This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.\n\nDNA analysis\n\nimmunologic technique\n\npharmacological study\n\niodine I 131 monoclonal antibody 3F8\n\n131I-3F8: Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.","id":"OG000","title":"131I-3F8"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With Response at 6 Months","type":"PRIMARY","unitOfMeasure":"Participants"}